Shanghai Caerulum Pharma Discovery
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Shanghai Caerulum Pharma Discovery
We are professional supplier of api.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
Avapritinib, also known as BLU-285, is a potent and selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants and is being developed as a highly targeted therapy for SM, a disorder of the mast cells in which a KIT Exon 17 mutation is the primary driver of disease. BLU-285 is currently being developed by Blueprint.
Shanghai Caerulum Pharma Discovery is the manufacturer of APIs and intermediates of some of the latest compounds in the market. Our focus is on cancer, diabetes and other therapeutic areas.
Shanghai Caerulum Pharma Discovery (CPD) offers high quality and reliable chemical products and integrated biological services including:
1) Best offer for existing APIs and intermediates
2) Custom-synthesis APIs and intermediates
3) DMPK
4) Biological screening
5) Drug Safety Evaluation
